Alan Faichney Joins the Board of Arrayjet as Non-Executive Chairman
News Sep 03, 2013
Arrayjet Ltd has announced that Alan Faichney has joined the Board as Non-Executive Chairman with immediate effect.
Alan has 33 years of commercial and company leadership experience, building international businesses in the Technology sector.
Beginning his career in the Aerospace industry, Alan later joined the oil exploration industry where he held key technical and strategic roles in product and market development.
More recently, Alan held the positions of Managing Director of Concept Systems Ltd. (a company he co-founded, and grew to a world-leader in the oil exploration business), Senior Vice President of Ion Geophysical Inc. (a US publicly quoted company, based in Houston), Chief Operating Officer at DEM-Solutions Ltd., a fast-growing Scottish software start-up with a global market, and Chief Executive Officer of Edinburgh Instruments, a global leader in the supply of high precision scientific instruments, which he recently sold to a publicly quoted Hong Kong company, as well as several non-executive Board positions with public and private companies.
Alan brings great experience in strategic analysis and planning in international business, detailed and effective operational abilities, formal negotiation skills and a wide experience of corporate finance and investment.
Commenting on the appointment, Dr Iain McWilliam, Chief Executive of Arrayjet Ltd said: "The Board is delighted that Alan is joining the team as Non-Executive Chairman. He has an enviable track record of enabling company growth and developing value in established businesses like Arrayjet. It was that experience, combined with his deep technical understanding that make Alan a great addition to our Board. We are very much look forward to working together as we continue to grow Arrayjet."
Alan Faichney commented: ''I am very excited by Arrayjet's technology, global market potential, and first-class people, and I look forward to working with them to build the business to the next level."
Scientists have identified sodium glucose transporter 2 (SGLT2) as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes tumor growth. The finding provides evidence that SGLT2 may be a novel biomarker that scientists can use to help diagnose precancerous lung lesions and early-stage lung cancers.READ MORE